Welcome

By selecting the Yes, leave Opcaseportalmy.com option you understand that you are leaving the website and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Malaysia is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third-party sites, you understand that you do so at your own risk.

The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Malaysia. If you reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.

Yes, opcaseportalmy.com Cancel

Treatment Algorithm for Postmenopausal Osteoporosis- AACE/ACE 2020

Treatment Algorithm
*10 year major osteoporotic fracture risk ≥ 20% or hip fracture risk ≥ 3%. Non-US countries/regions may have different thresholds.
  • References

    1. Camacho PM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update. Endocr Pract. 2020;26(Suppl 1):1-46.

View All
  • Important Safety Information:
    Osteoporosis Case Binder
    This curated collection of patient case studies aims to provide healthcare practitioners in the area of bone health, with a comprehensive understanding of risk-based treatment approach in the long-term management of patients living with osteoporosis.
    The patient cases were contributed by bone health experts from respective clinical setting, incorporating evidence-based discussions, guidelines and clinical considerations in the individualised treatment sequencing plans of different real-world scenarios..
    Please review full product information before prescribing
    For Healthcare Professionals Only.
    Please refer to full prescribing information prior to administration
    For information on Amgen products or to report an adverse event involving an Amgen product, please contact Medical Information at 1800 818 227 or medinfo.JAPAC@amgen.com
    SC-MAL-CP-00128-0425
    Endorsed By:
    Endorsed By